Inquirer on MSN2d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
SMALL CAP IDEA: 'Neuro-psych' specialist Solvonis emerges in takeover wave
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
BioSpace3d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
stocknews2d
3 Dividend Aristocrats With Consistent Payouts
Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...
stocknews3d
3 Dividend Growth Stocks Perfect for Long-Term Investors
Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with ...
pharmaphorum3d
GH Research leaps on psychedelic data in depression
GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...
Badger Herald1d
Ketamine’s path to Medicaid coverage in Wisconsin marked by optimism, gathering acceptance
Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...